In the print version of this interview, the first response contained an unrelated excerpt from the previous month's Q & A. The text begins with "who could mobilize..." and ends with "…results and more results." The error did not appear online in the HTML and PDF versions of the article. co r r i g e n da a n d e r r ata
Cerebral cavernous malformation (CCM) is a common vascular dysplasia that affects both systemic and central nervous system blood vessels. Loss of function mutations in the CCM2 gene cause CCM. Here we show that targeted disruption of Ccm2 in mice results in failed lumen formation and early embryonic death through an endothelial cell autonomous mechanism. We show that CCM2 regulates endothelial cytoskeletal architecture, cell-to-cell interactions and lumen formation. Heterozygosity at Ccm2, a genotype equivalent to that in human CCM, results in impaired endothelial barrier function. On the basis of our biochemical studies indicating that loss of CCM2 results in activation of RHOA GTPase, we rescued the cellular phenotype and barrier function in heterozygous mice with simvastatin, a drug known to inhibit Rho GTPases. These data offer the prospect for pharmacological treatment of a human vascular dysplasia with a widely available and safe drug.
Cerebral cavernous malformations are common vascular malformations that affect the systemic and central nervous system (CNS) vasculature with a prevalence of 1 in 200 to 250 individuals 1,2 in unselected populations. CCM consists of enlarged microvascular channels lined by a single layer of endothelium without smooth muscle support. Individuals with these vascular lesions are subject to an unpredictable risk of hemorrhage for which no pharmacologic therapy currently exists 3 . Even before overt hemorrhage all lesions are surrounded by hemosiderin-iron-laden deposits that result from extravascular blood and that can be sensitively detected by magnetic resonance imaging 4 -suggesting abnormalities in endothelial barrier function 5 . Although lesions have been described in a variety of vascular beds 6 , clinical manifestations are most common in the CNS, where the consequences of leak and hemorrhage can be stroke, seizure or death. A large proportion of cases are familial with an autosomal dominant pattern of inheritance. Genetic studies have shown that heterozygous loss of function mutations in CCM2-also known as osmosensing scaffold for mitogen-activated protein kinase kinase kinase-3 (OSM), and encoding a protein also known as malcavernin or MGC4607cause cavernous malformations 7, 8 . Two other structurally unrelated genes, KREV1 interaction trapped-1 (KRIT1)-also known as CCM1 (refs. 9,10)-and programmed cell death 10 (PDCD10)-also known as CCM3 (ref. 11)-have also been associated with CCM. Before the human genetic studies, there was little to recommend these genes as obvious candidate genes for any vascular disease.
CCM2 was identified in a screen for genes involved in the cellular response to osmotic shock 12 . These stress-activated pathways include signaling cascades involving Rho-family GTPases such as RHOA, RAC1 and CDC42, and mitogen-activated protein kinases (MAPKs) such as p38 and JNK. In fibroblasts, CCM2 is required for the assembly of a complex between the mitogen-activated protein kinase kinase kinase-3 and its substrate, mitogen-activated protein kinase kinase-3 (MKK3), to phosphorylate p38 in response to signaling from the GTPase RAC1 (ref. 12) .
Efforts to incorporate these biochemical insights into a molecular model to explain the pathogenesis of CCM have been plagued by controversy over the identity of the cell type in which CCM2 is required. Although a compromised vasculature defines CCM, there are compelling data to suggest a neuronal role in the etiology of the disease. First, the three genes involved in CCM are expressed neither specifically nor strongly in the endothelium in culture or in animal models [13] [14] [15] . Second, a precedent for a nonautonomous effect of a gene affecting vascular integrity exists: neural deletion of the gene encoding a v integrin disrupts the cerebral vasculature and causes hemorrhage in mice 16 . Conversely, KRIT1 can act as an effector of the small GTPase RAP1A in cultured endothelial cells 17 . The tissue specificity of Ccm2 function remains unknown. Here we seek to use genetically manipulated mice to understand the role of Ccm2 in development, elucidate the mechanism of signaling and explore potential therapeutic strategies for ameliorating CCM2 deficiency.
RESULTS
Ccm2 is required for angiogenesis A putative null allele of Ccm2 with a gene-trap-induced mutation was identified 14 . This allele has been termed Ccm2 Gt(RRG051)Byg (hereafter designated Ccm2 tr ), and consists of an insertion of the gene-trap vector into exon 6 of Ccm2 and a 45-nucleotide deletion of the genomic sequence 14 , disrupting transcription of Ccm2 (Supplementary Fig. 1a -c online). Mice heterozygous for Ccm2 tr are viable and fertile as previously reported 14 . We observed no homozygous mutant mice at weaning. We identified mutant embryos in mendelian ratios until embryonic day 9 (E9.0). Starting at E9.0, we noticed a gross phenotype in homozygous Ccm2 tr mice ( Supplementary Table 1 online). The homozygous mutant embryos failed to organize the yolk sac vasculature and showed evidence of growth arrest at E9.0 (data not shown). Pericardial effusions subsequently developed before embryo resorption at E11.5. No viable homozygous mutants were observed at E9.5 and beyond. The timing of death in these embryos is consistent with failed angiogenesis.
We studied embryos at E8.5 before the mutant phenotype could be grossly detected. Embryos were stained with antibodies against the endothelial cell surface protein CD31 (PECAM) or a-smooth muscle actin and examined with whole-mount confocal immunofluorescence microscopy or sectioned and studied by immunohistochemistry. The initial patterning of the dorsal aorta ( Supplementary Fig. 1d ,e) and yolk sac primary vascular plexus (data not shown) by vasculogenesis 18 was intact in mutants. Heart development was also normal (data not shown). After the initial vascular pattern was established, however, profound defects occurred in the development of subsequent vessels by angiogenesis ( Fig. 1a,b) . The first defects observed in mutant embryos included abnormalities of the first branchial arch artery and the intersomitic arteries at E8.5 (Fig. 1a,b and Supplementary  Fig. 1e ,f). The first branchial arch artery, required to connect the dorsal aorta to the heart, failed to form a proper lumen. Adjacent portions of the aorta were also narrow and irregular, whereas the previously normal caudal portion of the dorsal aorta become enlarged ( Supplementary  Fig. 1d ). Yolk sac vascular remodeling was abnormal (data not shown). The failure of the branchial arch arteries had profound physiologic consequences on the embryo. In vivo ultrasound studies showed that, despite normal frequency of cardiac contractions, circulation was not established in homozygous mutants ( Fig. 1c and Supplementary Movies 1 and 2 online). Branchial arch artery failure was not confined to the arteries of the first arch. The second and third pair of branchial arch arteries should normally form by E9.5. We injected India ink into the ventricles of mutant embryos at E9.5 and did not observe passage of ink into the dorsal aorta of mutants ( Fig. 1d ). Unlike the anterograde flow observed in wild-type littermates, ink passed retrogradely from the ventricle through the atrium and into the common cardinal vein in mutant embryos ( Fig. 1d) . Growth arrest and embryonic death resulted from the failed circulation first observed at E8.5.
Ccm2 is required in the endothelium The phenotype of mice with gene-trap mutations in Ccm2 establishes an essential role for this protein in angiogenesis. This mutation is present in all cells of the embryo and thus does not make clear which tissues require Ccm2 for normal function. To determine the tissue requirement for Ccm2, we developed mice with a conditional mutation in Ccm2 by Cre-lox technology ( Supplementary Fig. 2 online) . This allele is termed Ccm2 tm1Kwhi (hereafter referred to as Ccm2 fl ). The Ccm2 gene remains intact until the allele is exposed to Cre recombinase, which deletes exons 3-10 of Ccm2. Mating Ccm2 fl/+ mice with HPRT-Cre mice 19 expressing Cre recombinase in the germline resulted in a heritable mutant allele termed Ccm2 tm1.1Kwhi hereafter referred to as Ccm2 -). Homozygous Ccm2 -/mutant mice phenocopy the genetrap (Ccm2 tr/tr ) mutants ( Supplementary Fig. 2e ). Cre recombinase can also be expressed in a tissue-specific manner under the control of a variety of promoters. We subsequently examined a number of © 2009 Nature America, Inc. All rights reserved. tissue-restricted, somatic mutants for defects in angiogenesis. Mice lacking Ccm2 in the endothelium (Ccm2 fl/-;Tg(Tie2-Cre)) 20 resemble germline mutants with similar vascular defects and timing of embryonic death ( Table 1 and Fig. 2 ). Endothelial cell-specific deletion of Ccm2 is uniformly lethal during development ( Table 1 and data not shown).
The expression of Ccm2 in neural tissues and the predominance of CCM lesions in the CNS suggest a possible role for Ccm2 in neural cells. Mice lacking Ccm2 in neural tissues were generated with Cre driven by a nestin promoter (Ccm2 fl/-;Tg(Nes-Cre)) 21 . These mutant mice had no defects in angiogenesis at E9.0 and were found in the expected ratios at birth ( Table 1 and Fig. 2 ). Another key contributor to the milieu of endothelial cells in vivo is the smooth muscle cell. Mice lacking Ccm2 in smooth muscle cells were generated with a transgelin-Cre (Ccm2 fl/-;Tg(Tagln-Cre)) 22 . Like the mice lacking Ccm2 in neural tissues, mice lacking Ccm2 in smooth muscle were also found at birth, with normal vasculature at E9.0 ( Table 1 and Fig. 2 ). These data indicate an essential role for Ccm2 only in endothelial cells for the initial events of angiogenesis.
CCM2 regulates lumen formation via the actin cytoskeleton
Our genetic studies led us to evaluate the function of CCM2 in human endothelial cells. We detected CCM2 expression by real-time quantitative RT-PCR in human mictrovascular (dermal) endothelial cells (HMVECs) and human umbilical vein endothelial cells (HUVECs; Fig. 3a ). A single small interfering RNA (siRNA) construct specific for CCM2 (CCM2 siRNA) was able to decrease the amount of CCM2 transcripts by 80-90% in HMVECs and HUVECs (Fig. 3a) .
Endothelial cells in three-dimensional culture spontaneously develop tube-like structures that resemble the microvasculature and that model events in developmental angiogenesis 23 . We tested the role of CCM2 in lumen formation in vitro by comparing HUVECs treated with CCM2 siRNA with either a luciferase or a random negative control siRNA in this three-dimensional assay of tube morphogenesis (Fig. 3b,c and Supplementary Movies 3 and 4 online). Control HUVECs formed vacuoles that coalesced into tube-like structures over the course of 24 h, whereas CCM2-depleted HUVECs formed fewer lumens with a much smaller lumen cross-sectional area ( Fig. 3d,e ). This defect was observed at the single-cell stage before the formation of multicellular structures (Fig. 3d) . These observations suggest a crucial and endothelial intrinsic role for CCM2 in the development of precursor vacuoles as well as in the coalescence and © 2009 Nature America, Inc. All rights reserved. Numbers represent the number of embryos or neonates of the indicated genotypes found at the indicated time points. expansion of these structures to form the vascular lumen. Consistent with this hypothesis, we observed upregulation of CCM2 messenger RNA by RT-PCR in a time course parallel with lumen formation in control HUVECs (Fig. 3f) . The failure in lumen formation is not a consequence of insufficient endothelial migration or of an inability to form filopodial sprouts: HUVECs treated with CCM2 siRNA showed increased sprouting of cell processes when initially plated in threedimensional culture (Fig. 3g) , and HMVECs treated with CCM2 siRNA showed increased haptotactic migration ( Fig. 3h) .
Lumen formation is dependent upon the cellular cytoskeleton 24 . CCM2-deficient HMVECs had a marked increase in formation of actin stress fibers traversing the cell, with less cortical actin at the cell periphery ( Fig. 4a) . Actin redistribution correlated with a decrease in barrier function and increased permeability of the endothelial monolayer ( Fig. 4b,c ). We observed decreased electrical resistance and increased transit of macromolecules (horseradish peroxidase (HRP)) across CCM2-deficient monolayers compared to control cell monolayers (Fig. 4b,c ).
CCM2 regulates actin and MAPK via RHOA
The Rho family of small GTPases regulates many aspects of the structure and function of the cellular cytoskeleton. Impaired lumen formation 24 , increased formation of actin stress fibers and decreased barrier function 25 in endothelial cells suggest activation of RHOA. Consistent with the cellular phenotype, we observed increased active (GTP-bound) RHOA in CCM2-depleted HMVECs compared to control cells (Fig. 4d) . We found no change in the activation of RAC1 and found less basal activation of CDC42 (Fig. 4d) . By immunoprecipitation, we found that CCM2 binds RHOA and RAC1 but not CDC42 (Fig. 4e) . Inhibition of RHOA signaling either at the level of RHOA with C3 transferase 26 or downstream at the level of Rho kinase (ROCK), with the ROCK inhibitor Y-27632 (ref. 27 ) blocked the stress fiber response of CCM2-depleted HMVECs (Fig. 4f ). C3 transferase was also able to significantly rescue barrier function in these cells (Fig. 4g ).
CCM2 has also been implicated in MAPK signaling 12 . We used phospho-specific antibodies to profile the activation state of MAPK family members in the absence of CCM2 (Fig. 4h) . The main families of MAP kinases are the extracellular signal regulated kinases (ERKs), p38 and JNK, with p38 and JNK also known as stress-regulated protein kinases 28 . A reduction in CCM2 transcript levels did not affect the amount of either phosphorylated ERK or phosphorylated p38 but did increase phosphorylation of JNK and its upstream kinases MKK4 and MKK7. As GTPases can stimulate MAPK signaling, we tested whether increased JNK activation was the result of increased Rho activity by treating cells with the ROCK inhibitor Y-27632. ROCK inhibition decreased the activation of JNK (Fig. 4i) . These observations suggest that the loss of CCM2 leads to RHOA activation, causing activation of JNK with an associated change in endothelial phenotype including cytoskeletal changes, impaired lumen formation and increased migration and vascular permeability.
Simvastatin rescues CCM2 deficiency in vivo Humans with CCM have heterozygous mutations in CCM2 and suffer from vascular hemorrhage or leakage, but not from severe developmental angiogenic defects as observed in mice with homozygous mutations in Ccm2. To examine the role of Ccm2 in the disease state, we shifted our attention to mice heterozygous for Ccm2. We found no difference in vascular patterning (data not shown) or permeability to the intravascular dye Evans blue between heterozygous mice and wildtype controls (Fig. 5a) . Clinical reports suggest that physiological [29] [30] [31] © 2009 Nature America, Inc. All rights reserved. or genetic 32 stressors may have a role in disease pathogenesis. An association was observed between accelerated progression of CCM and increasing amounts of vascular endothelial growth factor (VEGF) 29 . Consistent with this clinical observation, we observed significantly increased permeability to Evans blue in Ccm2 +/tr mice in response to VEGF across a range of doses ( Fig. 5a ). Increased permeability was also observed in mice with endothelial-specific heterozygosity for Ccm2 (Fig. 5b) . These results demonstrate a role for Ccm2 in the endothelium for the maintenance of normal in vivo barrier function in adults aside from its role in embryonic development.
Our observations in vitro suggested that Rho inhibition might rescue the increased permeability of Ccm2-heterozygous mice. However, mice do not tolerate the ROCK inhibitor Y-27632 (data not shown), and the Rho inhibitor C3 transferase has poor cellular penetration, limiting its usefulness in vivo. Inhibitors of 3-hydroxy-3-methyl-glutaryl-CoA reductase (statins) have pleiotropic effects that include the inhibition of Rho GTPases. Simvastatin disrupts the production of key intermediaries in the cholesterol synthesis pathway necessary for RHOA isoprenylation 33, 34 and has been used as an inhibitor of Rho in vivo 35, 36 . In culture, we found that simvastatin reduced formation of actin stress fibers in both control and CCM2 siRNA-treated endothelial cells ( Fig. 5c ) and decreased haptotactic migration of CCM2-depleted HMVECs (Fig. 5d) . Simvastatin also decreased the phosphorylation of JNK in both control and CCM2 siRNA-treated cells (Fig. 5e) . In vivo, we found that pretreatment of mice with simvastatin significantly reduced the permeability © 2009 Nature America, Inc. All rights reserved. response of Ccm2 +/tr mice to VEGF with no effect on the induced permeability of Ccm2 +/+ mice (Fig. 5f) . These data suggest that the abnormal Rho GTPase activity observed in cells depleted of CCM2 is also present in mice with reduced levels of Ccm2.
DISCUSSION
We show here that mice lacking Ccm2 die in mid-gestation from failed angiogenesis and that these vascular defects are endothelial autonomous, providing what is to our knowledge the first in vivo evidence that any of the genes causing CCM are required in the endothelium. Using two distinct mutations in the Ccm2 gene, we show that Ccm2 is not required for the initial differentiation of endothelial cells from angioblast precursors (vasculogenesis) 18 , but, rather, is required for subsequent vessel formation and remodeling (angiogenesis) In mice lacking Ccm2, the branchial arch arteries, the first essential angiogenic vessels, fail to form a stable lumen. As a result, the heart is not functionally connected with the vasculature, and circulation fails to initiate. Subsequent growth and development of the embryo is severely impaired, and death ensues. Tissue-specific mutants show that selective deletion of Ccm2 in the endothelium is sufficient to reproduce the vascular defects, whereas mice lacking Ccm2 in neural or smooth muscle cells develop normally. Thus, Ccm2 is required in the endothelium for angiogenesis. The recognition of an autonomous function for Ccm2 in endothelial cells allowed us to examine previous biochemical studies in a new light. Such studies in fibroblasts and other nonendothelial cell types suggested a role for CCM2 as a scaffold tying RAC1 GTPase activity to p38 activation in response to osmotic stress 12 . Endothelial cells face stressors in the context of a monolayer of interacting cells. In addition to the maintenance of individual cell size and shape in the face of stress, endothelial cells must also maintain contact and barrier function with adjacent cells in the monolayer. One might expect that CCM2, as a key molecule in response to stress, would have a role in maintaining stable endothelial cytoskeletal architecture and cell-to-cell interactions. Our observations in CCM2-depleted HMVECs support this hypothesis: these cells showed a loss of cortical actin, increased formation of actin stress fibers and decreased endothelial barrier function, changes that are typically caused by activated RHOA GTPase 25 and that can be reversed by inhibitors of RHOA signaling.
Our observations suggest a model whereby a dynamic equilibrium between vascular stability and instability exists. The endothelium of a stable blood vessel provides crucial barrier functions by controlling fluid, nutrient and cellular transport between intravascular and extravascular compartments. The formation and maintenance of strong cell-to-cell contacts is a favorable characteristic of endothelial cells in a stable blood vessel. However, when challenged by injury or inflammation, the endothelium alters its phenotype and temporarily disrupts cell-to-cell junctions. In this destabilized state, the endothelium can initiate the required migration and angiogenesis responses to the stressor. In this model, CCM2 is required for endothelial cells to assume the stable phenotype, mediated at least in part by limiting RHOA activation 24, 37, 38 . Our cell culture data indicate that CCM2 regulates key aspects of the stabilized endothelium, including cellular architecture, barrier function, migration and tube morphogenesis. Loss of CCM2 favors the destabilized phenotype. In wild-type mice, with two functioning alleles of CCM2, the intensity and duration of instability after insult is limited. In heterozygous mice with only one functioning allele, there is a greater disruption of the stable state with increased permeability in response to VEGF. With the loss of both alleles of Ccm2 in the endothelium, stability cannot be achieved-existing vessels enlarge and excessive but dysfunctional angiogenic sprouts form, which are unable to develop stable lumens to allow functional circulation.
This model might also explain the development of cavernous angiomas in familial CCM. Previously, a 'two-hit' hypothesis involving biallelic somatic and germline mutations was proposed to explain the focal nature of vascular lesions in human CCM, supported by a single case report 32 in a cavernous angioma. Our in vivo experiments suggest the possibility that the second hit may not be limited to genetic disruptions but could also take the form of recurrent exposure to cytokines such as VEGF that are released locally in response to stress or inflammation. The unique importance of strong endothelial cell-to-cell interaction in the central nervous system might render this vascular bed particularly sensitive to such perturbations. The importance of a physiologic response to stress as a second hit could explain the clinical association between elevated levels of VEGF and the rapid progression of CCM 29 . Thus, in retrospect, a gene originally identified for its role in the cytoskeletal response to stress should have been an obvious candidate gene for human vascular dysplasias. The efficacy of statins in rescuing Ccm2-related vascular pathology in mutant mice suggests a pharmacological strategy for treating patients whose therapeutic options are currently limited to brain surgery or radiation.
METHODS
Fetal ultrasound. We studied pregnant mice under isoflurane anesthesia on a heated stage, with continuous monitoring of electrocardiogram and respiration. After laparotomy, we studied embryos within 45 min. We determined genotype correlation with ultrasound findings by recording the position of the embryos in the uterus relative to the position in the abdomen by ultrasound. We used a Vevo 660 ultrasound machine (VisualSonics) with a 40-MHz transducer for imaging. We used digital subtraction to illustrate circulating blood in static images (Supplementary Methods online). We determined heart rates by M-mode ultrasound.
Ink injection. We injected India ink as previously described 39 .
Endothelial cell vasculogenesis in three-dimensional collagen matrices. We suspended HUVECs (passages 2-5) within 3.75 mg ml -1 of collagen type I matrices and allowed them to undergo morphogenesis as described 40 . We fixed cultures with 3% glutaraldehyde for 30 min. We stained some cultures with 0.1% toluidine blue in 30% methanol and destained before photography and visualization. We performed time-lapse microscopy as previously described 41 with a Nikon TE2000U microscope with attached environmental chamber. We examined time-lapse images for total area of both vacuoles and lumens (n ¼ 5 independent fields) and total process length from all cells (n ¼ 10 fields). We quantified the number of lumens per field at 24 h (n ¼ 3 fields). We used Metamorph (Molecular Devices) software to trace and quantify lumen area and process length.
Endothelial cell haptotaxis. We examined haptotactic migration with a modified Boyden chamber assay (Neuro Probe). We coated polycarbonate membranes (8-mm pores) with human fibronectin (1 mg ml -1 , Biomedical Technologies) on the lower surface. We added HMVECs to the upper well (20,000 cells per well) in endothelial growth medium-2 and allowed them to migrate for 3 h. We fixed and stained the membranes (Hema3 kit, Fisher), removed nonmigrated cells and mounted the membrane on a glass slide. We counted the number of migrated cells per high-power field for multiple fields and replicates (control, n ¼ 12 fields; CCM2, n ¼ 8 fields). For simvastatin rescue experiments, we treated cells with either 10 mM simvastatin (Calbiochem) or ethanol carrier for 24 h before the assay (n ¼ 3 fields per condition).
Horseradish peroxidase permeability. We coated transwell inserts (Corning, 48-well, 3-mm pore) with human fibronectin and seeded them with 30,000 cells per well. We added HRP (25 mg ml -1 , Sigma) to the top of the insert. We asssayed solution from the bottom of the well for HRP 6 h later by colorimetric assay. We mixed the sample with guaicol (Sigma) and hydrogen peroxide (Fisher) and measured for absorbance at 490 nm (n ¼ 6 wells each).
Transendothelial resistance. We coated an electrode culture array (Applied Biophysics) with human fibronectin and seeded it at 50,000 cells per well. Three days after seeding, we serum-starved cells in endothelial basal medium-2 with 0.2% BSA overnight. We measured transendothelial resistance with an electric cell-substrate impedance sensing system (Applied Biophysics). We added cell-permeable C3 transferase (1 mg ml -1 ) to inhibit RHOA. For basal resistance, we measured 40 wells each; for Rho inhibition experiments, we measured six control wells each and ten C3 transferase wells each.
Miles assay. We performed tail vein injections of Evans blue (0.5% in normal saline, Sigma) in 8-12-week-old mice. Thirty minutes later, we injected either saline or VEGF-165 (R&D Systems, 10 ng) in multiple dermal sites. After an additional 30 min, we killed the mice, performed punch biopsies and eluted Evans blue from the biopsies in formamide (Invitrogen) overnight at 60 1C. We measured the absorbance of Evans blue at 620 nm, subtracting the background absorbance at 740 nm. We gave simvastatin (20 mg kg -1 ) as an intraperitoneal injection 26 h before and 2 h before the intradermal stimuli. For the VEGF dose-response experiment, we used five mice per group. For the permeability experiment with conditional Ccm2, we used five Ccm2 fl/+ mice, nine Ccm2 fl/mice and ten Ccm2 fl/+ ;Tg(Tie2-Cre) mice. For the simvastatin experiment, we used three mice with control treatment and four mice with simvastatin treatment.
Additional methodology. Mouse strains, histology, confocal immunofluorescence of embryos, cell culture, transfection of endothelial cells with siRNAs, RT-PCR, immunofluorescent cell staining, GTPase activation assays, immunoprecipitation and MAPK profiling are described in the Supplementary Methods online.
Mouse experiments. All mouse experiments were approved by the University of Utah Institutional Animal Care and Use Committee.
Statistical analyses. For in vitro lumen formation and cell process formation in three-dimensional culture, we performed statistical comparisons between treatment groups with a two-tailed paired samples t-test with an a value of 0.05. For transwell in vitro permeability, transendothelial resistance, endothelial cell migration and the Miles assay of dermal permeability, we made group comparisons by two-tailed Student's t-test with an a value of 0.05.
